Global Antisense and RNAi Therapeutics Market 2021-2025: Market is Poised to Grow by $1.61 Billion – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Antisense and RNAi Therapeutics Market 2021-2025” report has been added to ResearchAndMarkets.com’s offering.
The antisense and rnai therapeutics market is poised to grow by $ 1.61 bn during 2021-2025 progressing at a CAGR of 8% during the forecast period.
The market is driven by the high target affinity and specificity of RNAi therapeutics and availability of delivery platforms like nanoparticles and conjugates.
The report on antisense and rnai therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
This study identifies ease of standardization and large-scale manufacturing as one of the prime reasons driving the antisense and rnai therapeutics market growth during the next few years. ease of standardization and large-scale manufacturing will lead to sizable demand in the market.
The publisher’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading antisense and rnai therapeutics market vendors that include Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Bausch Health Companies Inc., Biogen Inc., Boehringer Ingelheim International GmbH, Dicerna Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Moderna Inc., Sanofi, and Sarepta Therapeutics Inc..
Also, the antisense and rnai therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Key Topics Covered:
Executive Summary
- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2020
- Market outlook: Forecast for 2020 – 2025
Five Forces Analysis
- Five forces analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Type
- Market segments
- Comparison by Type
- Antisense therapy – Market size and forecast 2020-2025
- RNAi therapy – Market size and forecast 2020-2025
- Market opportunity by Type
Market Segmentation by Application
- Infectious diseases
- Cardiovascular diseases
- Cancer
- Metabolic disorder
- Others
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America – Market size and forecast 2020-2025
- Europe – Market size and forecast 2020-2025
- Asia – Market size and forecast 2020-2025
- ROW – Market size and forecast 2020-2025
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Vendor landscape
- Landscape disruption
- Industry risks
- Competitive scenario
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Alnylam Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Biogen Inc.
- Boehringer Ingelheim International GmbH
- Dicerna Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc.
- Moderna Inc.
- Sanofi
- Sarepta Therapeutics Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
List of Exhibits
For more information about this report visit https://www.researchandmarkets.com/r/6j3w73
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
